Humacyte Capex To Operating Cash Flow vs Net Income Per Share Analysis

HUMAW Stock

USD 1.50 0.09 5.66%

Humacyte financial indicator trend analysis is much more than just examining Humacyte latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Humacyte is a good investment. Please check the relationship between Humacyte Capex To Operating Cash Flow and its Net Income Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Capex To Operating Cash Flow vs Net Income Per Share

Capex To Operating Cash Flow vs Net Income Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Humacyte Capex To Operating Cash Flow account and Net Income Per Share. At this time, the significance of the direction appears to have strong relationship.

The correlation between Humacyte's Capex To Operating Cash Flow and Net Income Per Share is 0.71. Overlapping area represents the amount of variation of Capex To Operating Cash Flow that can explain the historical movement of Net Income Per Share in the same time period over historical financial statements of Humacyte, assuming nothing else is changed. The correlation between historical values of Humacyte's Capex To Operating Cash Flow and Net Income Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Operating Cash Flow of Humacyte are associated (or correlated) with its Net Income Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per Share has no effect on the direction of Capex To Operating Cash Flow i.e., Humacyte's Capex To Operating Cash Flow and Net Income Per Share go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capex To Operating Cash Flow

Net Income Per Share

Most indicators from Humacyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.Enterprise Value is likely to climb to about 284.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	4.3M	6.2M	1.1M	1.1M
Depreciation And Amortization	8.3M	8.3M	7.7M	8.7M

Interest Expense Depreciation And Amortization

Humacyte fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Warrants	Long Term Debt	Common Stock Total Equity
Total Assets		0.32	0.29	0.01	0.49	-0.22	-0.87	-0.11	-0.45	0.98	-0.22	0.02	0.98	-0.13	0.15	-0.23	-0.04	0.49	0.47	-0.23	0.97	0.75	0.0	0.0	0.34	0.0
Short Long Term Debt Total	0.32		-0.29	0.83	-0.17	-0.96	-0.1	-0.9	0.26	0.51	-0.96	0.86	0.52	-0.89	0.9	0.25	-0.83	0.91	0.98	0.27	0.53	0.56	-0.59	-0.59	0.99	-0.59
Other Current Liab	0.29	-0.29		-0.17	0.95	0.37	-0.31	0.36	0.15	0.2	0.37	-0.24	0.18	0.62	-0.11	-0.98	0.13	-0.33	-0.22	-0.99	0.17	-0.14	0.08	0.08	-0.23	0.08
Total Current Liabilities	0.01	0.83	-0.17		-0.14	-0.88	0.16	-0.79	0.24	0.21	-0.88	0.78	0.21	-0.79	0.98	0.1	-0.98	0.8	0.81	0.13	0.22	0.41	-0.55	-0.55	0.78	-0.55
Total Stockholder Equity	0.49	-0.17	0.95	-0.14		0.31	-0.56	0.37	0.05	0.41	0.31	-0.28	0.4	0.55	-0.03	-0.96	0.13	-0.16	-0.07	-0.96	0.39	0.12	0.22	0.22	-0.11	0.22
Property Plant And Equipment Net	-0.22	-0.96	0.37	-0.88	0.31		-0.08	0.96	-0.2	-0.4	1.0	-0.91	-0.41	0.95	-0.89	-0.36	0.9	-0.9	-0.93	-0.37	-0.42	-0.48	0.71	0.71	-0.94	0.71
Net Debt	-0.87	-0.1	-0.31	0.16	-0.56	-0.08		-0.26	0.51	-0.84	-0.08	0.34	-0.84	-0.13	0.01	0.3	-0.22	-0.3	-0.28	0.3	-0.83	-0.76	-0.46	-0.46	-0.1	-0.46
Retained Earnings	-0.11	-0.9	0.36	-0.79	0.37	0.96	-0.26		-0.34	-0.27	0.96	-0.98	-0.28	0.91	-0.79	-0.37	0.85	-0.76	-0.82	-0.39	-0.29	-0.25	0.86	0.86	-0.89	0.86
Accounts Payable	-0.45	0.26	0.15	0.24	0.05	-0.2	0.51	-0.34		-0.38	-0.2	0.5	-0.38	-0.05	0.29	-0.23	-0.26	-0.16	0.1	-0.22	-0.37	-0.54	-0.44	-0.44	0.35	-0.44
Cash	0.98	0.51	0.2	0.21	0.41	-0.4	-0.84	-0.27	-0.38		-0.4	0.18	1.0	-0.31	0.34	-0.16	-0.22	0.66	0.65	-0.15	1.0	0.83	-0.08	-0.08	0.52	-0.08
Non Current Assets Total	-0.22	-0.96	0.37	-0.88	0.31	1.0	-0.08	0.96	-0.2	-0.4		-0.91	-0.41	0.95	-0.89	-0.36	0.9	-0.9	-0.93	-0.37	-0.42	-0.48	0.71	0.71	-0.94	0.71
Non Currrent Assets Other	0.02	0.86	-0.24	0.78	-0.28	-0.91	0.34	-0.98	0.5	0.18	-0.91		0.19	-0.82	0.79	0.24	-0.85	0.66	0.76	0.25	0.2	0.11	-0.9	-0.9	0.87	-0.9
Cash And Short Term Investments	0.98	0.52	0.18	0.21	0.4	-0.41	-0.84	-0.28	-0.38	1.0	-0.41	0.19		-0.32	0.34	-0.14	-0.22	0.66	0.65	-0.13	1.0	0.83	-0.09	-0.09	0.52	-0.09
Net Receivables	-0.13	-0.89	0.62	-0.79	0.55	0.95	-0.13	0.91	-0.05	-0.31	0.95	-0.82	-0.32		-0.78	-0.61	0.8	-0.88	-0.85	-0.62	-0.33	-0.49	0.61	0.61	-0.84	0.61
Common Stock Shares Outstanding	0.15	0.9	-0.11	0.98	-0.03	-0.89	0.01	-0.79	0.29	0.34	-0.89	0.79	0.34	-0.78		0.04	-0.95	0.84	0.89	0.06	0.35	0.5	-0.51	-0.51	0.87	-0.51
Non Current Liabilities Total	-0.23	0.25	-0.98	0.1	-0.96	-0.36	0.3	-0.37	-0.23	-0.16	-0.36	0.24	-0.14	-0.61	0.04		-0.09	0.31	0.19	1.0	-0.13	0.12	-0.14	-0.14	0.19	-0.14
Inventory	-0.04	-0.83	0.13	-0.98	0.13	0.9	-0.22	0.85	-0.26	-0.22	0.9	-0.85	-0.22	0.8	-0.95	-0.09		-0.78	-0.79	-0.11	-0.23	-0.34	0.69	0.69	-0.79	0.69
Other Current Assets	0.49	0.91	-0.33	0.8	-0.16	-0.9	-0.3	-0.76	-0.16	0.66	-0.9	0.66	0.66	-0.88	0.84	0.31	-0.78		0.96	0.32	0.67	0.81	-0.4	-0.4	0.85	-0.4
Other Stockholder Equity	0.47	0.98	-0.22	0.81	-0.07	-0.93	-0.28	-0.82	0.1	0.65	-0.93	0.76	0.65	-0.85	0.89	0.19	-0.79	0.96		0.21	0.66	0.71	-0.48	-0.48	0.96	-0.48
Total Liab	-0.23	0.27	-0.99	0.13	-0.96	-0.37	0.3	-0.39	-0.22	-0.15	-0.37	0.25	-0.13	-0.62	0.06	1.0	-0.11	0.32	0.21		-0.12	0.14	-0.14	-0.14	0.21	-0.14
Total Current Assets	0.97	0.53	0.17	0.22	0.39	-0.42	-0.83	-0.29	-0.37	1.0	-0.42	0.2	1.0	-0.33	0.35	-0.13	-0.23	0.67	0.66	-0.12		0.84	-0.09	-0.09	0.53	-0.09
Common Stock	0.75	0.56	-0.14	0.41	0.12	-0.48	-0.76	-0.25	-0.54	0.83	-0.48	0.11	0.83	-0.49	0.5	0.12	-0.34	0.81	0.71	0.14	0.84		0.14	0.14	0.5	0.14
Net Tangible Assets	0.0	-0.59	0.08	-0.55	0.22	0.71	-0.46	0.86	-0.44	-0.08	0.71	-0.9	-0.09	0.61	-0.51	-0.14	0.69	-0.4	-0.48	-0.14	-0.09	0.14		1.0	-0.62	1.0
Warrants	0.0	-0.59	0.08	-0.55	0.22	0.71	-0.46	0.86	-0.44	-0.08	0.71	-0.9	-0.09	0.61	-0.51	-0.14	0.69	-0.4	-0.48	-0.14	-0.09	0.14	1.0		-0.62	1.0
Long Term Debt	0.34	0.99	-0.23	0.78	-0.11	-0.94	-0.1	-0.89	0.35	0.52	-0.94	0.87	0.52	-0.84	0.87	0.19	-0.79	0.85	0.96	0.21	0.53	0.5	-0.62	-0.62		-0.62
Common Stock Total Equity	0.0	-0.59	0.08	-0.55	0.22	0.71	-0.46	0.86	-0.44	-0.08	0.71	-0.9	-0.09	0.61	-0.51	-0.14	0.69	-0.4	-0.48	-0.14	-0.09	0.14	1.0	1.0	-0.62

Click cells to compare fundamentals

Humacyte Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Humacyte Capex To Operating Cash Flow vs Net Income Per Share Analysis

Capex To Operating Cash Flow vs Net Income Per Share

Capex To Operating Cash Flow vs Net Income Per Share Correlation Analysis

Correlation Coefficient

Capex To Operating Cash Flow

Net Income Per Share

Humacyte fundamental ratios Correlations

Humacyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Humacyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Warrants	+ 1.0	Net Tangible Assets

Total Liab	- 0.99	Other Current Liab
Non Currrent Assets Other	- 0.98	Retained Earnings
Inventory	- 0.98	Total Current Liabilities
Non Current Liabilities Total	- 0.98	Other Current Liab
Total Liab	- 0.96	Total Stockholder Equity
Non Current Liabilities Total	- 0.96	Total Stockholder Equity